The opportunity cost of androgen suppression in locally advanced prostate cancer.

Abstract

T he use of androgen suppression therapy (AST) and radiotherapy for locally advanced prostate cancer has become the standard of care worldwide. At the same time, it has become clear that AST carries significant risk for side effects. Recently, Denham and colleagues have reported initial quality of life (QoL) results from the TROG 03.04 RADAR trial. The… (More)
DOI: 10.1038/aja.2012.166

Topics

  • Presentations referencing similar topics